Skip to main content
Top
Published in: Abdominal Radiology 2/2024

13-11-2023 | Computed Tomography | Pancreas

Preoperative evaluating early recurrence in resectable pancreatic ductal adenocarcinoma by using CT radiomics

Authors: Gang Wang, Weijie Lei, Shaofeng Duan, Aihong Cao, Hongyuan Shi

Published in: Abdominal Radiology | Issue 2/2024

Login to get access

Abstract

Objective

To investigate the feasibility of a radiomics model based on contrast-enhanced CT for preoperatively predicting early recurrence after curative resection in patients with resectable pancreatic ductal adenocarcinoma (PDAC).

Methods

One hundred and eighty-six patients with resectable PDAC who underwent curative resection were included and allocated to training set (131 patients) and validation set (55 patients). Radiomics features were extracted from arterial phase and portal venous phase images. The Mann-Whitney U test and least absolute shrinkage and selection operator (LASSO) regression were used for feature selection and radiomics signature construction. The radiomics model based on radiomics signature and clinical features was developed by the multivariate logistic regression analysis. Performance of the radiomics model was investigated by the area under the receiver operating characteristic (ROC) curve.

Results

The radiomics signature, consisting of three arterial phase and three venous phase features, showed optimal prediction performance for early recurrence in both training (AUC = 0.73) and validation sets (AUC = 0.66). Multivariate logistic analysis identified the radiomics signature (OR, 2.58; 95% CI 2.36–3.17; p = 0.002) and clinical stage (OR, 1.60; 95% CI 1.15–2.30; p = 0.007) as independent predictors. The AUC values for risk evaluation of early recurrence using the radiomics model incorporating clinical stage were 0.80 (training set) and 0.75 (validation set).

Conclusion

The radiomics-based model integrating with clinical stage can predict early recurrence after upfront surgery in patients with resectable PDAC.
Appendix
Available only for authorised users
Literature
1.
2.
go back to reference Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019;20:1493-505.CrossRefPubMedPubMedCentral Arnold M, Rutherford MJ, Bardot A, et al. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study. Lancet Oncol 2019;20:1493-505.CrossRefPubMedPubMedCentral
3.
go back to reference Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260:372-7.CrossRefPubMed Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg 2014;260:372-7.CrossRefPubMed
4.
go back to reference Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016;34:2541–55.CrossRefPubMed Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline. J Clin Oncol 2016;34:2541–55.CrossRefPubMed
5.
go back to reference Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 2018;267:936-45.CrossRefPubMed Groot VP, Rezaee N, Wu W, et al. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. Ann Surg 2018;267:936-45.CrossRefPubMed
6.
go back to reference Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 2019;269:1154-62.CrossRefPubMed Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg 2019;269:1154-62.CrossRefPubMed
7.
go back to reference Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395-406.CrossRefPubMed Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395-406.CrossRefPubMed
8.
go back to reference Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:2324-8.CrossRefPubMed Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017;35:2324-8.CrossRefPubMed
9.
go back to reference National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, 2021. NCCN Clinical Practice Guidelines in Oncology Web site. National Comprehensive Cancer Network. Pancreatic Adenocarcinoma, 2021. NCCN Clinical Practice Guidelines in Oncology Web site.
10.
go back to reference Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the American pancreatic association. Radiology 2014;270:248-60.CrossRefPubMed Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the American pancreatic association. Radiology 2014;270:248-60.CrossRefPubMed
11.
go back to reference Springfeld, C., Neoptolemos, J. P. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Nat Rev Clin Oncol 2022;5:285-6.CrossRef Springfeld, C., Neoptolemos, J. P. The role of neoadjuvant therapy for resectable pancreatic cancer remains uncertain. Nat Rev Clin Oncol 2022;5:285-6.CrossRef
12.
go back to reference Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.CrossRefPubMed Aerts HJ, Velazquez ER, Leijenaar RT, et al. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun 2014;5:4006.CrossRefPubMed
13.
14.
15.
go back to reference Sauerbrei E, Royston P, Binder H, Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:5512-28.CrossRefPubMed Sauerbrei E, Royston P, Binder H, Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med 2007;26:5512-28.CrossRefPubMed
16.
go back to reference He M, Chen X, Wels M, et al. Computed tomography-based radiomics evaluation of postoperative local recurrence of pancreatic ductal adenocarcinoma. Acad Radiol 2023;30:680-8.CrossRefPubMed He M, Chen X, Wels M, et al. Computed tomography-based radiomics evaluation of postoperative local recurrence of pancreatic ductal adenocarcinoma. Acad Radiol 2023;30:680-8.CrossRefPubMed
17.
go back to reference Adamu M, Nitschke P, Petrov P, et al. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91.CrossRefPubMed Adamu M, Nitschke P, Petrov P, et al. Validation of prognostic risk scores for patients undergoing resection for pancreatic cancer. Pancreatology 2018;18:585-91.CrossRefPubMed
18.
go back to reference Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590-1601.CrossRefPubMed Tanaka M, Mihaljevic AL, Probst P, et al. Meta-analysis of recurrence pattern after resection for pancreatic cancer. Br J Surg. 2019;106:1590-1601.CrossRefPubMed
19.
go back to reference Jones RP, Psarelli EE, JacksonR, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038-48.CrossRefPubMedPubMedCentral Jones RP, Psarelli EE, JacksonR, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154:1038-48.CrossRefPubMedPubMedCentral
20.
go back to reference Karamitopoulou E, Wenning AS, Acharjee A, et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut. 2023;72:1523-33.CrossRefPubMed Karamitopoulou E, Wenning AS, Acharjee A, et al. Spatially restricted tumour-associated and host-associated immune drivers correlate with the recurrence sites of pancreatic cancer. Gut. 2023;72:1523-33.CrossRefPubMed
21.
go back to reference Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257:87-96.CrossRefPubMed Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamic-enhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257:87-96.CrossRefPubMed
22.
go back to reference Prokesch RW, Chow LC, Beaulieu CF. et al. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 2002;224:764-8.CrossRefPubMed Prokesch RW, Chow LC, Beaulieu CF. et al. Isoattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology 2002;224:764-8.CrossRefPubMed
23.
go back to reference Ishigami K, Yoshimitsu K, Irie H, et al. Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography. Eur J Radiol 2009;69:139-46.CrossRefPubMed Ishigami K, Yoshimitsu K, Irie H, et al. Diagnostic value of the delayed phase image for iso-attenuating pancreatic carcinomas in the pancreatic parenchymal phase on multidetector computed tomography. Eur J Radiol 2009;69:139-46.CrossRefPubMed
24.
go back to reference Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas--616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-9.CrossRefPubMed Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas--616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-9.CrossRefPubMed
25.
go back to reference Shi H, Wei Y, Cheng S, et al. Survival prediction after upfront surgery in patients with pancreatic ductal adenocarcinoma: Radiomic, clinic-pathologic and body composition analysis. Pancreatology. 2021;21:731-7.CrossRefPubMed Shi H, Wei Y, Cheng S, et al. Survival prediction after upfront surgery in patients with pancreatic ductal adenocarcinoma: Radiomic, clinic-pathologic and body composition analysis. Pancreatology. 2021;21:731-7.CrossRefPubMed
26.
go back to reference Kulkarni A, Carrion-Martinez I, Jiang NN, et al. Hypovascular pancreas head adenocarcinoma: CT texture analysis for assessment of resection margin status and high-risk features. Eur Radiol 2020;30:2853-60.CrossRefPubMed Kulkarni A, Carrion-Martinez I, Jiang NN, et al. Hypovascular pancreas head adenocarcinoma: CT texture analysis for assessment of resection margin status and high-risk features. Eur Radiol 2020;30:2853-60.CrossRefPubMed
27.
go back to reference Chu LC, S. Park, S. Kawamoto, et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. Am. J. Roentgenol 2019;213:349-57.CrossRef Chu LC, S. Park, S. Kawamoto, et al. Utility of CT radiomics features in differentiation of pancreatic ductal adenocarcinoma from normal pancreatic tissue. Am. J. Roentgenol 2019;213:349-57.CrossRef
28.
go back to reference Kim DW, Lee SS, Kim SO, et al. Estimating recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma by using pancreatic CT: development and validation of a risk score. Radiology 2020;296:541-51.CrossRefPubMed Kim DW, Lee SS, Kim SO, et al. Estimating recurrence after upfront surgery in patients with resectable pancreatic ductal adenocarcinoma by using pancreatic CT: development and validation of a risk score. Radiology 2020;296:541-51.CrossRefPubMed
29.
go back to reference Tang TY, Li X, Zhang Q, et al. Development of a novel multiparametric MRI radiomic nomogram for preoperative evaluation of early recurrence in resectable pancreatic cancer. J Magn Reson Imaging 2020;52:231-45.CrossRefPubMed Tang TY, Li X, Zhang Q, et al. Development of a novel multiparametric MRI radiomic nomogram for preoperative evaluation of early recurrence in resectable pancreatic cancer. J Magn Reson Imaging 2020;52:231-45.CrossRefPubMed
30.
go back to reference Guo SW, Shen J, Gao JH, et al. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Surgery 2020;168:1003-14.CrossRefPubMed Guo SW, Shen J, Gao JH, et al. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma. Surgery 2020;168:1003-14.CrossRefPubMed
31.
go back to reference Imamura M, Nagayama M, Kyuno D, et al. Perioperative predictors of early recurrence for resectable and borderline-resectable pancreatic cancer. Cancers (Basel) 2021;13:2285CrossRefPubMed Imamura M, Nagayama M, Kyuno D, et al. Perioperative predictors of early recurrence for resectable and borderline-resectable pancreatic cancer. Cancers (Basel) 2021;13:2285CrossRefPubMed
Metadata
Title
Preoperative evaluating early recurrence in resectable pancreatic ductal adenocarcinoma by using CT radiomics
Authors
Gang Wang
Weijie Lei
Shaofeng Duan
Aihong Cao
Hongyuan Shi
Publication date
13-11-2023
Publisher
Springer US
Published in
Abdominal Radiology / Issue 2/2024
Print ISSN: 2366-004X
Electronic ISSN: 2366-0058
DOI
https://doi.org/10.1007/s00261-023-04074-x

Other articles of this Issue 2/2024

Abdominal Radiology 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.